Mesoblast (MESO) Expected to Announce Earnings on Thursday

Mesoblast (NASDAQ:MESO) is projected to post its results before the market opens on Thursday, February 26th. Analysts expect Mesoblast to post earnings of ($0.2370) per share and revenue of $30.6790 million for the quarter.

Mesoblast Price Performance

Shares of Mesoblast stock opened at $16.88 on Friday. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -19.18 and a beta of 2.15. The firm’s 50-day moving average price is $18.06 and its two-hundred day moving average price is $16.84. The company has a current ratio of 1.99, a quick ratio of 1.77 and a debt-to-equity ratio of 0.11. Mesoblast has a 1-year low of $9.61 and a 1-year high of $21.50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Institutional Trading of Mesoblast

A number of hedge funds have recently modified their holdings of MESO. Quadrature Capital Ltd bought a new position in shares of Mesoblast during the fourth quarter worth $479,000. AQR Capital Management LLC raised its position in shares of Mesoblast by 80.5% during the fourth quarter. AQR Capital Management LLC now owns 25,215 shares of the company’s stock worth $455,000 after purchasing an additional 11,242 shares during the period. &PARTNERS bought a new position in shares of Mesoblast during the 4th quarter valued at about $334,000. Opal Capital LLC bought a new position in shares of Mesoblast during the 4th quarter valued at about $307,000. Finally, Marshall Wace LLP acquired a new position in shares of Mesoblast in the 4th quarter valued at approximately $286,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.